A $700 million publicly-traded medical services provider was interested in an early- stage stem cell therapeutic opportunity that, if successful, could dramatically improve outcomes in its area of clinical focus. One of the firm’s strategic partners had just initiated Phase I clinical trials using this innovative approach and had approached the company about a potential investment to support their efforts.
On behalf of its client, SSB analyzed the current state of the prospective partner’s development efforts, their proposed go-to-market strategy, anticipated financial needs and competing research efforts in the same field. Based on its analysis, SSB recommended a "go slow" strategy, working to keep the discussions going, provide limited support in selected areas of need and otherwise stay close to critical developments in the field.